SynthesisTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2013
A systematic review of p53 as a biomarker of survival in patients with osteosarcoma.
Synthesis in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03336554 (Indentifying Epigenetic Biomarkers From Peripheral Blood of Osteosarcoma Patients Based on hMe-Seal Technique), which is not on this map. Cited by 31 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Indentifying Epigenetic Biomarkers From Peripheral Blood of Osteosarcoma Patients Based on hMe-Seal Technique
Who cites it
31 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Prognostic significance of matrix metalloproteinase 9 expression in osteosarcoma: A meta-analysis of 16 studies.Medicine · 2018Pooled it
- The prognostic significance of p53 expression in gastric cancer: a meta-analysis.Journal of cancer research and clinical oncology · 2015Pooled it
- A systematic review of matrix metalloproteinase 9 as a biomarker of survival in patients with osteosarcoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Meta-analysis of the prognostic value of smad4 immunohistochemistry in various cancers.PloS one · 2014Pooled it
- Rsk2 inhibition induces an aneuploid post-mitotic arrest of cell cycle progression in osteosarcoma cells.Cell death discovery · 2025Article
- Building a Therapeutic Bridge Between Dogs and Humans: A Review of Potential Cross-Species Osteosarcoma Biomarkers.International journal of molecular sciences · 2025Review
- PDK1, associated with glycolytic metabolism, is a potential prognostic biomarker in osteosarcoma.PloS one · 2025Article
- Abnormal signal pathways and tumor heterogeneity in osteosarcoma.Journal of translational medicine · 2023Article
- Histological Severity Risk Factors Identification in Juvenile-Onset Recurrent Respiratory Papillomatosis: How Immunohistochemistry and AI Algorithms Can Help?Frontiers in oncology · 2021Article
- Identification of osteosarcoma driver genes using a network method.Oncology letters · 2020Article
- Cold atmospheric plasma inhibits the growth of osteosarcoma cells by inducing apoptosis, independent of the device used.Oncology letters · 2020Article
- Anticancer Effects of Constituents of Herbs Targeting Osteosarcoma.Chinese journal of integrative medicine · 2019Review
- TP53 in bone and soft tissue sarcomas.Pharmacology & therapeutics · 2019Review
- Nucleotide variants and protein expression of TP53 in a Sri Lankan cohort of patients with head and neck cancer.Molecular medicine reports · 2019Article
- Identification of Prognostic and Predictive Osteosarcoma Biomarkers.Medical sciences (Basel, Switzerland) · 2019Review
- Metastasis in the wild: investigating metastasis in non-laboratory animals.Clinical & experimental metastasis · 2019Review
- Abnormally expressed long non-coding RNAs in prognosis of Osteosarcoma: A systematic review and meta-analysis.Journal of bone oncology · 2018Article
- Hedgehog signalling in the tumourigenesis and metastasis of osteosarcoma, and its potential value in the clinical therapy of osteosarcoma.Cell death & disease · 2018Review
- Comparative review of human and canine osteosarcoma: morphology, epidemiology, prognosis, treatment and genetics.Acta veterinaria Scandinavica · 2017Review
- Screening of candidate key genes associated with human osteosarcoma using bioinformatics analysis.Oncology letters · 2017Article
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma is the most common malignant bone tumor, and the prognosis of patients with osteosarcoma is still unsatisfactory with low survival rates. There are many studies assessing the prognostic role of upregulated p53 in patients presenting osteosarcoma, and there is no consistent finding. To summarize the existing evidence about whether the presence of upregulated p53 was a biomarker of survival in patients with osteosarcoma, we performed a systematic review and meta-analysis of relevant publications. We assessed the effect of upregulated p53 on the 3-year overall survival and the 3-year disease-free survival by calculating the pooled odds ratio (OR) with corresponding 95% confidence interval (95%CI). Fifteen studies with a total of 609 patients with osteosarcoma were finally included into the systematic review and meta-analysis. Compared with osteosarcoma patients with low or undetectable p53, patients with upregulated p53 were obviously associated with decreased 3-year overall survival (OR = 0.29, 95 %CI 0.19-0.43, P < 0.001). In addition, patients with upregulated p53 were obviously associated with decreased 3-year disease-free survival (OR = 0.06, 95 %CI 0.02-0.23, P < 0.001). The results from the systematic review and meta-analysis highlight that p53 is an effective biomarker of survival in patients with osteosarcoma. In addition, more studies with a large sample size are needed to identify the effect of p53 expression in osteosarcoma patients.
Indexed as
Identifiers
24014053What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.